Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (136)	3/1/2001 3:32:02 PM
From: DaveAu	Respond to of 164

Jim, Given that the value of the ONC held by SYB is more than the entire value of SYB, I don't consider news on ONC to be off topic at all. In fact, I think it's the main topic. This is actually a very significant release. The key is whether the product works on metastatic cancer. There are thousands of products that work well when injected into a single tumour. The use of cyclosporine is very interesting as well - to slow down the immune system so the virus is active longer. Dave

To: Jim Oravetz who wrote (136)	12/13/2001 1:14:54 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 164

Oncolytics Gets Positive Phase I Reolysin Trial Results Dow Jones Newswires CALGARY -- Oncolytics Biotech Inc. (ONCY) received positive interim results from its Phase I clinical trial of Reolysin, a potential cancer therapeutic for RAS activated tumors and cancers. In a news release, the company said the Phase I trial was designed as a dose escalation study to determine the safety and tolerance of Reolysin in late-stage cancer patients who have failed all other treatment options. It said none of the patients to date has experienced any serious adverse events related to the virus, nor were there any dose-limiting toxicities detected in any patient. As secondary endpoints, Oncolytics measured tumor response at both the treated lesion as well as remote metastatic sites. It said evidence of viral activity in tumors was observed, which ranged from changes in tumor structure to partial and complete tumor regression in the injected tumors. It noted that 50% of injected tumors in the first four of six groups demonstrated evidence of viral activity. Preliminary evidence of remote tumor responses were also noted in the first four groups, it said. Oncolytics said it is now in a position to initiate multiple follow-up trials of Reolysin to better determine its efficacy and safety profile. The first of these studies, a T2 prostate cancer trial, is expected to start enrollment in January. Other clinical trial protocols are being prepared. It said the Phase I study enrolled a total of 18 patients in six groups of three patients each and examined intratumoral administration of Reolysin. The company said detailed final results of the study are expected to be presented next year at an international cancer conference, and will include final safety, efficacy, and immune data on all the patients. Oncolytics is a biotechnology company. Company Web Site: oncolyticsbiotech.com